71results about How to "Good prospects for clinical application" patented technology

The invention relates to chemical crosslinking type glucan hydrogel and a preparation method thereof, and belongs to the technical field of biomedical functional polymer materials. The preparation method comprises the steps that glucan is dissolved in water at room temperature and then placed in an ice-water bath, and sodium periodate is added to obtain a mixed solution; the mixed solution is stirred for reaction for 2-6 h on the room temperature and dark conditions; the stirred solution is dialyzed with a regenerated cellulose dialysis bag in deionized water, and after dialysis is completed, freeze drying is performed to obtain partial hydroformylation glucan solids with the hydroformylation degree of 40-60 percent; the obtained partial hydroformylation glucan solids are dissolved in the deionized water to obtain an aqueous hydroformylation glucan solution, a multi-amino crosslinking agent is added in the aqueous hydroformylation glucan solution to be mixed evenly at the room temperature, and then the glucan hydrogel is prepared. The chemical crosslinking type glucan hydrogel is prepared by taking natural glucan macromolecules with the good biosafety as a material basis through chemical crosslinking of the partial hydroformylation glucan and the multi-amino crosslinking agent.

The invention discloses an injectable calcium phosphate / natural polymer composite material. The injectable calcium phosphate / natural polymer composite material is an injectable paste material formed by uniformly dispersing approximately spherical calcium phosphate ceramic particles with the particle size of 20-100 microns in a natural polymer (or its derivative) solution, wherein calcium phosphate is hydroxyapatite or diphasic calcium phosphate, 0-20% of bioactive glass can be added, the natural polymer or its derivative is one or more of sodium hyaluronate, collagen, chitosan, chondroitin sulfate and the like. The invention further discloses a preparation method of an injectable calcium phosphate / natural polymer composite material and a method for performing facial mini-plastic surgery by adopting the method. After the injectable calcium phosphate / natural polymer composite material is implanted in a body by adopting the method, a natural polymer in the material is degraded and absorbed, the calcium phosphate ceramic particles are fused with an autologous bone tissue together, a lasting shaping effect can be achieved, and clinical application prospect is good.

The invention discloses a photothermal-chemotherapy combined therapeutic agent based on Prussian blue and a preparation method of the therapeutic agent. The therapeutic agent is characterized in that the therapeutic agent is of a liposome-like structure, Prussian blue nanoparticles are used as a core, a medicine-carrying bimolecular layer is formed outside the core through hydrophobic-hydrophobic interaction between two different amphipathic surfactants, and anticancer medicine is encapsulated in the medicine-carrying bimolecular layer. The therapeutic agent combines Prussian blue with the anticancer medicine to realize photothermal-chemotherapy synergistic treatment, so that the problem that chemotherapy medicine is low in specificity and human body utilization rate is solved, the defect that photothermal treatment is incomplete is overcome, treatment efficiency is improved greatly, and the therapeutic agent has good clinical application prospect.

The invention provides a culture solution for retinal pigment epitheliums (hESC-RPE). The culture solution is characterized in that the culture solution contains, 96-97.5 volume fractions of a basic culture medium, 1 volume fraction of non-essential amino acids (NEAA), 1 volume fraction of L-glutamine, 0.5-21 volume fractions of an N2 additive, a component a and a component b. The invention further provides a preparation method of the culture solution and a method for culturing the retinal pigment epitheliums (hESC-RPE) by using the culture solution. Compared with existing culture media, the culture medium of the culture solution is simple composition, the costs are lower, no ethical problem is related, and cell proliferation can be promoted.

An oral liquid Xinshenghua is prepared from cane sugar, sorbic acid, polysorbate, and 7 Chinese-medicinal materials including Chinese angelica root, motherwort, Chuan-xiong rhizome, peach kernel, etc. Its preparing process is also disclosed.

The invention discloses a pulmonary nodule diagnosis marker and an application, and belongs to the technical field of biotechnology detection. The invention provides an application of one or more of PLA2G6, PLA2G7, AKR1C1, AKR1C3, LTA4H and PTGER4 genes as biomarker molecules for diagnosing pulmonary nodule diseases, and the biomarkers can be used for assisting in living tissue examination and helping to confirm related pulmonary diseases. The accuracy rates (areas under ROC curves) of the genes for identifying the sarcoidosis in distinguishing healthy people, lung adenocarcinoma patients andpulmonary tuberculosis patients are 96.5%, 90.9%, 89.1%, 87.5%, 87.2% and 85.8% in sequence, and the comprehensive accuracy rate is 90.9%. According to the invention, a certain quantity of clinical samples are collected for research and verification, the research result conforms to clinical practice, and the pulmonary nodule diagnosis marker has good clinical application prospects.

The invention discloses a solid tumor inhibiting medicine composition composed of arctigenin and a pyrimidine nucleotide synthetic inhibitor, wherein a weight ratio of the components is 1:0.001-1000, and preferably 1:0.01-100. Pharmacodynamic tests show that, the medicine composition provides substantial synergetic effects in the treatments of solid tumors, especially leukemia. The medicine composition provided by the invention has advantages of wide tumor inhibiting spectrum, small side effect, low treatment cost, and good prospect in clinical application.

The invention discloses an asiaticoside oral liquid and making method, which is made of total asiaticoside and corresponding auxiliary material. The invention has stable quality and obvious effect to be intaked safely and heathly, which improves the quality standard and enlarges the drug kinds to satisfy the need of the people for drugs.

The invention relates to a multifunctional fusion protein for Her2+ tumor cells, wherein the multifunctional fusion protein includes a single-chain antibody variable region (scFv) specifically recognizing a tumor antigen Her2, an SIRP[alpha] extracellular functional region shielding a signal of a tumor immunosuppressive protein CD47, a high-affinity IgG1Fc binding to an Fc receptor, and non-functional amino acid fragments for connecting various functional regions. The invention also relates to preparation and an application of the fusion protein. The recombinant fusion protein not only can recognize Her2 positive tumor cells, but also can shield CD47 immunosuppressive signaling pathways. At the same time, the high-affinity Fc part can enhance the immune response of immune cells to tumors,and has good clinical prospects and wide application range.

The invention provides a nifuratel gel and the related preparation method. The invention is made of nifuratel as the raw material, a gel substrate carbomer and other relative auxiliary materials and used to cure vulvar and vaginal infections and vaginal mixed infections caused by germs, trichomonads and candidas. The invention has the advantages of obvious curative effect, relative stable quality, and is convenient to carry and take, and is safe and sanitary. The invention is comprehensively improved in quality, and enriches the medication varieties after the formulation is changed, thus the invention has great significance for further meeting and guaranteeing the medication requirements of people.

The invention discloses a full-degradable metal-based closure clamp. The full-degradable metal-based closure clamp is applicable to closing blood vessels or tubular tissues in an endoscope operation.The full-degradable metal-based closure clamp has the following advantages that the closure clamp is made of degradable pure magnesium or magnesium alloy; the closure clamp is of a V-shaped structure,and an upper arm and a lower arm of the closure clamp are connected through an arc tail for removing stress concentration; the head of the upper arm and the head of the lower arm of the closure clampare provided with closing-locking structures which achieve the closing effect; the head and shoulder of the upper arm and the head and shoulder of the lower arm of the closure clamp are provided withclamping structures which are matched with clamp-application pincers; clamping teeth which can be cooperatively closed are arranged on a clamping surface of the closure clamp body. When the clamp-application pincers clamp and close the closure clamp, the upper arm elastic structure of the closure clamp is in contact with the lower arm structure to form closure, and the matched clamping teeth on the clamping surface are closely attached to blood vessels / tissues to make the lumens closed. Due to the closure mode of the closure clamp for the blood vessels / tissues and the degradability and mechanical properties endowed by magnesium-based materials, the closing capability is high, the clamp does not easily shed, body fluid is completely degraded, and clinic requirements can be well met.

The invention relates to the field of biotechnology, and in particular relates to an aptamer capable of simultaneously identifying OdDHL ([N-(3-oxododecanoyl)-L-homoserine lactone]) and BHL (N-butanoyl-L-homoserine lactone) and an application thereof. OdDHL and BHL are signaling molecules of las and rhl signaling pathways of a pseudomonas aeruginosa population effect system, respectively; and the activation of the two signaling pathways is capable of starting expression of a pseudomonas aeruginosa virulence gene. An aptamer bonding OdDHL and BHL in high affinity is screened by using a competition method. The aptamer has a population effect system for interfering pseudomonas aeruginosa and the potential for inhibiting the expression of the pseudomonas aeruginosa virulence gene. The affinity of bonding the aptamer with OdDHL and BHL is equivalent to that of an antibody, and the preparation process is simple and easy to operate and low in cost.

The invention provides an application of chlorogenic acid to preparing a medicine for treating Hutchinson-Gilford syndrome. Chlorogenic acid can treat Hutchinson-Gilford syndrome effectively and has a better curative effect than a positive medicine rapamycin; and chlorogenic acid is safe and has few side effects and a favorable clinical application prospect.

The invention provides a Chinese herbal medicine compound preparation used for nourishing the kidney-yin and consolidating Chong Vessel for preventing miscarriage and the related preparation method. The preparation is used for treating early threatened abortion (fetal leakage and unstable fetal movement) kidney yin deficiency the preparation comprises following main ingredients: radix polygoni multiflori, rehmannia root, desertliving cistanche (processed), teasel toot, Chinese taxillus twig, ramulus uncariae cum uncis, cuscuta seed, sojutsu var(stir-fried), baical skullcap root and white peony root. With strong pertinence, obvious curative effect, relative stable quality and no toxic and side effect, the invention provides a safe and effective fetus-guarding drug.

Use of Fructus schisandrae in preparation of medicaments for preventing and reducing toxicity and side effects of antineoplastic agents. The toxicity and side effects of antineoplastic agents are cardiovascular toxicity, hepatotoxicity, nephrotoxicity, suppression of bone marrow, immunosuppression, or alopecia etc induced by antineoplastic agents. Fructus schisandrae and extracts thereof, especially ethanol extracts, schisandrin B, are effective in reducing antineoplastic agent's toxicity and side effects.

The invention discloses injectable temperature-sensitive hydrogel for cartilage regeneration and repair and a preparation method of the injectable temperature-sensitive hydrogel. The injectable temperature-sensitive hydrogel is prepared from the following components: 1-10g / 100ml of a chitosan solution, 0.5-15g / 100ml of a sodium glycerophosphate solution, 4-15g / 100ml of a collagen solution and 2-10 parts of decalcified bone matrix powder. The injectable temperature-sensitive hydrogel for cartilage regeneration and repair has a temperature-sensitive characteristic, the sol can be implanted into an organ or a defect part in a body through an injector or an endoscope, so that the gel is quickly formed in situ, and the effect of the gel is exerted.

The invention discloses a six-dimensional miniature force and torque sensor used for force feedback of a minimally invasive surgical robot, and belongs to the technical field of miniature force sensors. The six-dimensional miniature force and torque sensor aims to solve the problem that the doctor cannot apply an accurate acting force on a corresponding affected part since contact information between the doctor and a diseased tissue is difficult to obtain during the minimally invasive surgery process. The six-dimensional miniature force and torque sensor comprises an instrument shaft, a miniature sensor, a traction device and a detection circuit, wherein the miniature sensor is composed of a Stewart platform-structure elastic body, 12 strain gauges, an upper connecting piece, a lower connecting piece and a sleeve shell, the upper connecting piece comprises an upper connecting ring section and a cylindrical upper supporting platform, and the lower connecting piece comprises a lower connecting ring section and a cylindrical lower supporting platform; the traction device is composed of a sleeve and a pull hook, the upper connecting ring section is fixed to the instrument shaft in an interference sleeving manner, the lower connecting ring section is connected with the sleeve through a pin shaft, the bottom end of the sleeve is provided with a sleeve bottom, and the center of the sleeve bottom is welded and fixed to the pull hook; and the detection circuit is connected with the strain gauges through twisted pairs. The six-dimensional miniature force and torque sensor is used for three-dimensional miniature force detection.

The invention provides a ketoconazole gel and a preparation method thereof. The ketoconazole gel is used for treating vulval and vaginal infection and vaginal mixed infection which are caused by bacteria, trichomonad and candida albicans. The ketoconazole gel mainly consists of ketoconazole, hydroxypropyl-beta-cyclodextrin, carbomer, chitosan and poloxamer, improves stability of the ketoconazole and quanlity, does not cause drug resistance phenomena, and is high in safety and suitable for treatment of vaginal infection of women in the gestation period. The ketoconazole gel is characterized by having temperature susceptibility and biological adhesion and slowly performing long-acting release so that the ketoconazole gel has the advantages of facilitating use of patients and being high in patient compliance, convenient to take, safe, hygienic and the like. The quality standard is improved comprehensively, pharmacy variety is enriched after dosage form is changed, and the ketoconazole gel and the preparation method have great significant meaning for further meeting and guaranteeing pharmacy requirements of users.

The invention discloses a hair follicle tissue composite preserving fluid, a preparation method thereof and a preserving method for maintaining in-vitro activity of hair follicles, and belongs to the technical field of cell cryopreservation. The preserving method for maintaining in-vitro activity of hair follicles comprises the following steps: 1, taking a hair follicle tissue composite preservation solution, and pre-cooling at 4 DEG C; taking in-vitro unit hair follicles, rinsing the in-vitro unit hair follicles with a Ringer's solution, and removing blood clots and impurities; the rinsed unit hair follicles are placed in a cold hair follicle tissue composite preserving fluid to be fully immersed, and the preserving temperature needs to be maintained at 4 DEG C; 2, removing the hair follicle tissue composite preserving fluid, rinsing unit hair follicles with Ringer's solution, and transplanting the hair follicles into a human body after removing residual preserving fluid. The hair follicle tissue composite preserving fluid is composed of a basic preserving fluid and an auxiliary preserving fluid, wherein the basic preserving fluid is composed of a solute, a solvent and a pH value regulator. The method has the advantages that no risk doubt component exists, the stored hair follicle can be directly used for clinical transplantation treatment after being simply flushed with normal saline, and the method is safe and effective and has a good clinical application prospect.

The invention discloses an olmesartan medoxomil amlodipine tablet and a preparation method thereof. The olmesartan medoxomil amlodipine tablet is prepared by smashing, tabletting and coating olmesartan medoxomil, amlodipine besylate, silicified microcrystalline cellulose, pregelatinized starch, crosslinked sodium carboxymethyl cellulose, calcium hydrogen phosphate, sodium carboxymethyl starch, magnesium stearate, titanium dioxide, talcum powder, a coating premix and the like, has an ideal clinical therapeutic effect, and effectively improves the stability of the drug release of the compound medicine, the raw materials in the preparation process are all subjected to powder processing, the preparation process is simple, and the finally obtained olmesartan medoxomil amlodipine tablet has strong stability, fast dispersion, good absorption and a good clinical application prospect.

The invention relates to the technical field of pharmaceutical chemistry, and in particular, relates to an application of a celecoxib derivative OSU-03012 in preparation of anti-tubercle bacillus drugs, and an application of the celecoxib derivative OSU-03012 in preparation of drugs for treatment of pulmonary tuberculosis, and also relates to an anti-tubercle bacillus drug composition. The celecoxib derivative OSU-03012 has anti-tubercle bacillus and anti-drug-resistant tubercle bacillus activities, so the celecoxib derivative OSU-03012 can be used as a leading compound in treatment of tubercle bacillus infectious diseases (such as pulmonary tuberculosis). Of course, the celecoxib derivative OSU-03012 itself can also be used for preparing the drugs for treating tuberculosis, thereby havinggood clinical application prospects.

The invention discloses a codon-optimized Chi3L1 gene. The nucleotide sequence of the gene is shown in SEQ ID NO.1. The invention further discloses a method for expressing and purifying Chi3L1 protein through the Chi3L1 gene. The method for obtaining Chi3L1 recombinant protein is provided and is low in cost and easy and convenient to implement, the Chi3L1 recombinant protein has very strong immunity activity and a function of promoting growth of tumors, can be taken as an active drug for immunity research and a drug target for development of anti-tumor drugs and has a good foundation and clinical application prospect.

The invention discloses a lotion for treating hand-foot syndrome caused by a targeted drug and a preparation method thereof. The lotion is prepared from the following raw materials: 70-100g of honeysuckle, 45-75g of schizonepeta, 58-65g of cortex dictamni, 80-100g of radix scrophulariae, 50-65g of angelica sinensis, 85-95g of rhizoma smilacis glabrae, 27-40g of lithospermum and 20-45g of raw liquorice. The lotion is capable of relieving the uncomfortable symptoms, such as erythema, pain and desquamation, of the patient through the traditional Chinese medicine composition, relieving the psychological burden of the patient, increasing the comfort level, increasing the opportunity for the subsequent treatment of the patient, and has the advantages of high safety, small side effect and better clinical practice value.

The invention relates to a multifunctional fusion protein for the type III epidermal growth factor receptor deletion-mutant receptor (EGFRvIII). The multifunctional fusion protein comprises an antibody functional area for specifically recognizing the tumor antigen EGFRvIII, a SIRP alpha extracellular functional area for shielding a tumor surface immunosuppressive protein CD47, a high-affinity human antibody IgG1Fc for recognizing an Fc receptor, and non-functional amino acid fragments for linking the functional areas; the invention also relates to preparation and application of the fusion protein. The fusion protein provided by the invention can meet the needs of tumor immunotherapy for patients; the recombinant fusion protein not only can recognize EGFRvIII-positive tumor cells, but alsocan shield a CD47 immunosuppressive signaling pathway; furthermore, the high-affinity Fc part can increase the immune response of immune cells to tumor cells; therefore, the multifunctional fusion protein can enhance the function of inhibiting tumor growth after being clinically applied, and has a good clinical prospect and a wide application scope.

The invention discloses an application of 6-[4-[2-(1-piperidyl)ethoxy]phenyl]-3-(4-pyridyl)pyrazolo[1,5-A]pyrimidine in preparation of a transcription inhibitor medicine. The invention also discloses a pharmaceutical composition which is a preparation prepared by taking 6-[4-[2-(1-piperidyl)ethoxy]phenyl]-3-(4-pyridyl)pyrazolo[1,5-A]pyrimidine as an active ingredient accompanied by pharmaceutically acceptable accessories or auxiliary components. The 6-[4-[2-(1-piperidyl)ethoxy]phenyl]-3-(4-pyridyl)pyrazolo[1,5-A]pyrimidine disclosed by the invention can effectively inhibit cell transcription and induce tumor cell apoptosis, realizes an exact curative effect on lung cancer, liver cancer or cervical cancer, and has a good prospect in clinical application.

The invention discloses a solid tumor resisting medicine composition with arctigenin and nitrosourea alkylating agent anti-tumor medicines as active components. The weight ratio of arctigenin to nitrosourea alkylating agent anti-tumor medicines is 1:0.001-1000, and preferably 1:0.01-600. The anti-tumor medicine composition provided by the invention is advantaged in clear components, wide anti-tumor spectrum, substantial treatment effect against various tumors, low price, low side-effects, and good clinical application prospect.

The invention discloses a lung cancer screening kit. The lung cancer screening kit comprises an optional reagent which is used for testing expression level of LCK (Lymphocyte Cell-specific protein-tyrosine Kinase). The invention further discloses use of the reagent for testing the expression level of the LCK in preparation of reagents for lung cancer screening. According to the kit disclosed by the invention, through testing the expression level of the LCK, the risk of suffering from a lung cancer of a testee can be judged; the kit can be applied to the clinical auxiliary diagnosis of the lung cancer so as to provide an effective basis for taking related therapy measures or decisions by a patient; the clinical application prospect is good.

The invention discloses a lung cancer screening kit which comprises an optional reagent used for detecting the HSP60 expression level. The invention further discloses application of the reagent for detecting the HSP60 expression level in preparing a reagent for screening lung cancer. The risk of lung cancer of crowds to be examined can be judged when the kit is used for detecting the HSP60 expression level, the kit can be used for clinic lung cancer auxiliary diagnosis, effective basis is provided for patients for adopting relevant treatment measures or decisions, and the clinic application prospect is good.

The invention provides a nucleotide sequence as shown in SEQ ID NO:1 and further provides application of the nucleotide sequence and a kit for detecting bacterial infection of schizothorax prenanti. The nucleotide sequence can serve as an auxiliary biomarker for detecting bacterial infection of schizothorax prenanti. By detection of Hsp60 mRNA expression level of blood, hepatopancreas, mesonephroi and or spleen tissues of schizothorax prenanti shoal, risk screening of bacterial infection of schizothorax prenanti can be realized, and the clinical application prospect is excellent.